Index
bacterial infections
acid-fast bacteria, 321
Actinomyces,
100-103
allergic/acute vaginitis, 99
bacterial vaginitis, 96,
97
curved anaerobic bacterial vaginitis, 98
desquamative inflam m atory vaginitis, 99
esophagus, 379
female genital tract, 96-105
follicular cervicitis, 104-105,
106
foreign-body vaginitis, 98
genococcus vaginitis, 98
gram-positive and negative bacteria, 321
granuloma inguinale, 99
lactobacillus vaginitis, 98
Langerhans cell histiocytosis, 100
Leptotrichia buccalis,
103-104,
105
malacoplakia, 100
meningitis, 441
micrococcus vaginitis, 97
mycoplasma, 104
respiratory tract, 321
tuberculosis, 99-100
vaginal lactobacillosis, 98,
99
balantidiasis, protozoal infection, 543
banding analysis, chromosomes
karyotyping, 25,
26,
28
and nucleus, 4
Barr body, chromatin, 5
Barrett's esophagus, 376, 380-383
dysplasia and adenocarcinoma,
381-383
molecular techniques, 1080
and small-cell carcinoma, 384
Bartholin gland, 273
carcinoma, 279
infections, 274
parasitic infections, 123
basal cell adenoma, salivary glands, 616
basal cell carcinoma (basal cell epithelioma)
in children, 937
skin, 502, 503
vulva, 277
basal cell hyperplasia, 140-141
basophil leukocytes, effusions, 531-532
"basophilic" structures, hematoxylin, 5,
6
”BB shot",
Trichomonas vaginalis,
124
BCC (benign cellular changes),
NILM category, 82
BCG therapy, 431
BCLlgene,
lymphomas, 31, 41
BCL2
gene, lymphomas, 30, 33
BCL3
gene, lymphomas, 33
BCL6
gene, lymphomas, 33-34
BCL10
gene, lymphomas, 31
bDNA (branched DNA), 118
Behcet's disease, vagina, 279
Bellini's duct carcinoma, 833
benign fibrous histiocytoma, 478
benign lesions, character, 11
benign proliferative reactions, cervix
atypia, 144-145,
148
cell destruction, 147
hyperkeratosis, 137-138,
139
inflam m ation, 147-150
karyorrhexis, 147
parakeratosis, 138-139
reactive and regenerative changes,
145-153,
147, 148
benign proliferative reactions,
cervix
(Continued)
cell destruction, 147
cytology, 146-147
cytolysis, 147
degenerative, 147,
149
epithelial abnormalities, 149-150
human papillomavirus and cancer,
150-151
immunosuppression, 150
inflammation-associated, 147-150
IUDs, 150
karyorrhexis, 147
repair, key features, 146-147
unsatisfactory quality, 147, 149
reserve cell hyperplasia, 140-141
squamous metaplasia, 139-144
immature, 141-143,
142, 143
mature, 143-144
Ber-EP4, marker, 1053,
1063, 1064
berylliosis, 682
Bethesda System
anal-rectal cytology, reporting, 87-88
ancillary testing, 87
automated review, 87
clinical inform ation, 80
Criteria Committee, 78
educational notes/suggestions, 87
endocervical adenocarcinoma, 221
endocervical adenocarcinoma in situ, 218
general categorization, 81
goals, 77-78, 88
historical background, 77-78
and human papillomavirus, 113
interobserver reproducibility, 87
interpretation/result, 60, 81-87
atypical squamous cells
see
atypical
squamous cells (ASC)
endometrial cells, 82
glandular cells, 85-87
negative for intraepithelial lesion or
malignancy, 82
squamous intraepithelial lesions, 82-83,
84-85
laboratory practice, impact on, 81
management guidelines, 81
other screening systems compared,
251
patient/specimen identification and
technical interpretability, 80
quality indicators, 80-81
report format, 78
sampling o f transformation zone, 81
specimen adequacy, 78-81
squamous cellularity, 80
and squamous intraepithelial
neoplasia, 153
TBS, 2001,
79-80
glandular cells, reporting, 85
sample adequacy assessment, 66
specimen adequacy categories, 78
vulvar intraepithelial neoplasia, 275
BG-8, marker, 1053
pHCG (human chorionic gonadotrophin),
267, 268
bile duct adenoma, 891,
892
biliary tract
adenocarcinoma, 401, 403
molecular techniques, 1080
normal histology/cytology, 401
biopsies
see also
staining
aspiration
see
FNA (fine-needle aspiration)
core needle, 714-715, 969
large-needle thyroid, 635, 647
punch, 502
scrapings
see
scrapings
transthoracic needle, 303
Birbeck granules, Langerhans cell
histiocytosis, 100
birefringent uric acid crystals, 413,
414
Birt-Hogg Dube syndrome,
kidney cancer, 819,
821
black thyroid syndrome, 636-637
bladder
diverticulosis of, 414
and radiation, 956
washings, 410, 411
bladder cancer
bleeding, 410
in children, 943-945
cyclophosphamide, 430, 431, 961
examination o f symptomatic patients, 410
follow-up after treatment, 410
and screening, 54, 409-410
small-cell carcinoma, 426
therapy, 960-961, 962-963
transitional cell carcinoma, 446
blastoid cells, lymphomas, 699
blastomycosis, pulmonary, 321-322
bleeding
bladder cancer, 410
endometrial adenocarcinoma, 256
infections, 92
uterine, dysfunctional, 264
bleomycin, anticancer therapy, 958-959
BLIMP1
(B-lymphocyte-induced maturation
protein 1), 33
blood group antigen predictors,
urinary tract, 433
blood-culturing method, cytogenetics, 23
body cavities
see
serous cavities
body fluids, 993-994
cell preparation for, 994-995
cerebrospinal fluid preparation, 995
macroscopic differences in,
994
staining, 998, 1000
bone lesions
adamantinomas, 501-502
benign, 496
cartilage tumors, 492-496
in children, 941-942
epithelioid and epithelial
neoplasms, 501
fibrohistiocytic tumors, 498
hematopoitic tumors, 498-500
melanotic neuroectodermal tum or of
infancy, 941-942
osteogenic tumors, 496-497
round cell bone tumors, pediatric, 941
borderline mucinous cystadenoma, 935
borderline nodule, liver, 885
borderline serous cystadenocarcinoma, in
children, 935
brain
see also
central nervous system (CNS)
fine needle aspiration biopsy, 439
metastatic disease, 446
parenchyma disease, 441
1093
previous page 1076 ComprehensiveCytopathology 1104p 2008 read online next page 1078 ComprehensiveCytopathology 1104p 2008 read online Home Toggle text on/off